Read our COVID-19 research and news.

Webinar Technology

Linking lipids and disease: Making the connection between fatty acids, inflammation, and tissue homeostasis

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Linking lipids and disease: Making the connection between fatty acids, inflammation, and tissue homeostasis

06 May 2020

12:00 p.m. ET

Register to watch recording

Speakers

Lipids are extremely diverse molecules, but their diversity, structure, and exact function are not well understood. Precise determination of each molecular species of lipid is a prerequisite for understanding their functions in physiology and disease, and for discovering novel, bioactive lipid-derived mediators that may have therapeutic benefits. Liquid chromatography tandem mass spectrometry (LC-MS/MS) is a powerful method for analyzing lipid metabolites, providing insight into the structure and function of endogenous lipid metabolites that regulate inflammation and tissue homeostasis. Examples include the omega-3 polyunsaturated fatty acids (PUFAs) eicosapentaenoic acid and docosahexaenoic acid, and precursors to the specialized proresolving mediators (SPMs), such as the resolvin, protectin, and maresin families. PUFAs are thought to be beneficial in maintaining tissue homeostasis and inflammation, while SPMs have demonstrated proresolving and anti-inflammatory actions as well as the ability to enhance microbial clearance by the immune system. Using targeted lipidomics systems, fatty acid–derived mediators can be comprehensively monitored to elucidate the role of omega-3 PUFA-derived mediators in controlling the inflammatory response and its resolution, highlighting their exciting potential for identifying targets for the treatment of inflammatory diseases.

During the webinar, the speakers will:

  • Outline how the latest mass spectrometry techniques, such as Q-TOF and TripleQ, are being applied in lipid research
  • Describe recent advances in understanding the role of omega-3 PUFAs in controlling the inflammatory response
  • Explain the structural elucidation of SPMs derived from PUFAs during inflammation resolution
  • Highlight recent results, using resolvin D4 as example, showing how SPMs reduce venous thrombosis burden and activate resolution of inflammation
  • Answer your questions live during the broadcast.

This webinar will last for approximately 75 minutes.

Speaker bios

Makoto Arita, Ph.D.

Keio University/RIKEN
Tokyo, Japan

Dr. Arita received his Ph.D. from the Graduate School of Pharmaceutical Sciences, University of Tokyo in 1997. After postdoctoral training at Brigham and Women’s Hospital/Harvard Medical School, he became an instructor at Harvard Medical School in 2003. He returned to Japan in 2006 as an associate professor at the University of Tokyo. Since 2014, he has headed the Laboratory for Metabolomics at the RIKEN Center for Integrative Medical Sciences as its team leader. He also serves as a visiting professor in the Graduate School of Medical Life Science at Yokohama City University. In 2016, he became professor of physiological chemistry and metabolism at Keio University Faculty of Pharmacy. Dr. Arita is currently project leader on the LipoQuality Program project, a Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research on Innovative Area. His work on the biology of lipoquality seeks to understand the molecular mechanisms through which specific lipid structures elicit their biological functions, and how the coordinated dynamics of these lipids maintain cellular and tissue homeostasis.

Charles N. Serhan, Ph.D.

Harvard Medical School
Cambridge, MA

Dr. Serhan is the Simon Gelman Professor of Anaesthesia (biochemistry and molecular pharmacology) at Harvard Medical School and professor of Oral Medicine, Infection, and Immunity at Harvard School of Dental Medicine. He is also director of the Center for Experimental Therapeutics and Reperfusion Injury at Brigham and Women’s Hospital. He received a B.S. degree in biochemistry from Stony Brook University, followed by a doctorate in experimental pathology and medical sciences from New York University School of Medicine. Between 1981 and 1986, he was a visiting scientist and postdoctoral fellow at the Karolinska Institutet in Stockholm with Nobel laureate Bengt Samuelsson. He joined the faculty at Harvard Medical School in 1987 and received an honorary degree from Harvard University in 1996. He has received several awards, including a U.S. National Institutes of Health MERIT award, the William Harvey Research Institute John Vane Medal (2008), the Ross Prize in Molecular Medicine (2016), and the International Eicosanoid Research Foundation’s 2017 Lifetime Achievement Award (2017), and was elected an Honorary Life Member by the Society for Leukocyte Biology (2019). He was elected as a fellow of AAAS in 2011. His research focuses on structural elucidation of bioactive small molecules and pathways that activate the resolution of acute inflammation. His group has characterized several new families of lipid-derived, local-acting chemical mediators and has designed novel therapeutic approaches using these structures as biotemplates.

Sean Sanders, Ph.D.

Science/AAAS
Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently, Dr. Sanders is the Director and Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here